Security
Charming Medical Limited Class A Ordinary Shares · MCTA
MCTANASDAQCommon stockHistorical · closed Oct 19, 2026CIK 2035992Updated Nov 6, 2026
Current security for this SEC filerMCTA · NASDAQ
MCTA price & chart
Historical security
This listing closed Oct 19, 2026. Live provider charts are shown only for current listings.
Current security: MCTA
About the company
Charming Medical Limited (the “Company”) is a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. The Company integrates TCM principles with modern technology to enhance quality of life and promote holistic well-being. Through its four wellness centers in Hong Kong, the Company offers a wide range of services, including womb-warming therapy, pelvic detox therapy, moxibustion, prenatal massage, and traditional abdominal binding, designed to address women’s health issues such as menstrual irregularities, hormonal imbalance, and postpartum recovery. Under its “Beauty Lab” brand, Charming Medical Limited also develops and distributes TCM-inspired supplements and beauty products, such as uterine care patches, probiotic washes, and nourishing herbal formulations, aimed at improving women’s constitution and vitality. In addition, the Company provides technical training, dietary therapy consultancy, and franchise opportunities to extend its wellness philosophy to other practitioners and entrepreneurs. For more information, please visit https://charmingmed.com.
In the news
Shareholders who lost money in shares Charming Medical Ltd. (NASDAQ: MCTA) Should Contact Wolf Haldenstein Immediately News provided by Wolf Haldenstein Adler Freeman & Herz LLP Jan 07, 2026, 08:12 ET Share this article Share to X Share this article Share to X Lead Plaintiff Deadline is February 17, ↗
Recent filings
Show 2 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 |
|---|---|
| ASSETS | |
| AssetsUSD | 9,868,667Source |
| Property, Plant and Equipment, NetUSD | 606,901Source |
| Current assets: | |
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,699,273Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 201,477Source |
| Inventory, NetUSD | 25,623Source |
| Assets, CurrentUSD | 8,174,597Source |
| Operating Lease, Right-of-Use AssetUSD | 724,119Source |
| LIABILITIES AND EQUITY | |
| LiabilitiesUSD | 4,687,705Source |
| Stockholders’ equity: | |
| Additional Paid in CapitalUSD | 5,097,241Source |
| Retained Earnings (Accumulated Deficit)USD | 96,793Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -14,790Source |
| Stockholders' Equity Attributable to ParentUSD | 5,180,962Source |
| Liabilities and EquityUSD | 9,868,667Source |
| Current liabilities: | |
| Liabilities, CurrentUSD | 4,332,148Source |
| Operating Lease, Liability, CurrentUSD | 366,660Source |
| Operating Lease, Liability, NoncurrentUSD | 355,557Source |
| Additional Financial Items | |
| Long-term DebtUSD | 185,799Source |
cash flow · annual statements
| Line item | FY 2026 |
|---|---|
| Cash flows from operating activities: | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -22,648Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |
| Changes in operating assets and liabilities: | |
| Increase (Decrease) in Accounts ReceivableUSD | -194,424Source |
| Increase (Decrease) in InventoriesUSD | -1,174Source |
| Deferred Income Tax Expense (Benefit)USD | 67,983Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -1,215,931Source |
| Cash flows from investing activities: | |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -179,015Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 339,560Source |
| Cash flows from financing activities: | |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 5,292,156Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,699,273Source |
| Supplemental disclosure of cash flow information: | |
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 15,799Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -14,708Source |
| Additional Financial Items | |
| Debt Securities, Realized Gain (Loss)USD | 12,103Source |
| DepreciationUSD | 216,074Source |
| Gain (Loss) on InvestmentsUSD | 72,651Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 11,796Source |
| Income Tax Expense (Benefit)USD | 156,114Source |
| InterestExpenseNonoperatingUSD | 15,799Source |
| Investment Income, InterestUSD | 72,651Source |
| Net Income (Loss) Attributable to ParentUSD | -22,648Source |
| Nonoperating Income (Expense)USD | 162,703Source |
| Operating ExpensesUSD | 4,836,950Source |
| Operating Lease, ExpenseUSD | 459,914Source |
| Other Nonoperating Income (Expense)USD | 50,763Source |
| Payments to Acquire InvestmentsUSD | 11,052Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 2,618,481Source |
| Unrealized Gain (Loss) on InvestmentsUSD | 22,621Source |
income statement · annual statements
| Line item | FY 2026 |
|---|---|
| Total RevenueUSD | 4,807,713Source |
| Cost of Goods and Services Sold | —Source |
| Gross Profit (Calculated) · Derived | — |
| Operating Income (Loss)USD | -29,237Source |
| Other Nonoperating Income (Expense)USD | 50,763Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 133,466Source |
| Income Tax Expense (Benefit)USD | 156,114Source |
| Net Income (Loss) Attributable to ParentUSD | -22,648Source |
| Earnings Per Share, BasicUSD per share | 0Source |
| Earnings Per Share, DilutedUSD per share | 0Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 16,150,055Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 16,150,055Source |
| Interest Expense (non-operating)USD | 15,799Source |
| Additional Financial Items | |
| Debt Securities, Realized Gain (Loss)USD | 12,103Source |
| Gain (Loss) on InvestmentsUSD | 72,651Source |
| Interest ExpenseUSD | 15,799Source |
| Investment Income, InterestUSD | 72,651Source |
| Marketing and Advertising ExpenseUSD | 803,483Source |
| Nonoperating Income (Expense)USD | 162,703Source |
| Operating ExpensesUSD | 4,836,950Source |
| Operating Lease, ExpenseUSD | 459,914Source |
| Other General and Administrative ExpenseUSD | 546,946Source |
| Other IncomeUSD | 20,364Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 2,618,481Source |
Filing attachments
ea031087501ex99-1.htm · 6-K · 2026-11-05
Exhibit 99.1 Charming Medical Limited Announces Receipt of Nasdaq Delisting Determination Notice. Hong Kong, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Charming Medical Limited (Nasdaq: MCTA) (the “Company”), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced that it received a delisting determination letter, dated October 29, 2026, from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Na…
Read attachment ↗ea030667101ex99-1.htm · 6-K · 2026-09-29
Exhibit 99.1 Charming Medical Limited Units 1803-1806, 18/F, Hang Lung Centre 2-20 Paterson Street, Causeway Bay, Hong Kong NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on October 23, 2026 at 10:30 a.m., Hong Kong Time (October 22, 2026 at 10:30 p.m., Eastern Time) (or any adjournment(s) or postponement(s) thereof) Notice is hereby given that an extraordinary general meeting (the “EGM”) of the shareholders of Charming Medical Limited, a BVI business company incorpora…
Read attachment ↗ea030667101ex99-2.htm · 6-K · 2026-09-29
Exhibit 99.2 Control Number Registered Number: of Shares: Shareholder: ───────────────────────────────────────────── Charming Medical Limited Units 1803-1806, 18/F, Hang Lung Centre 2-20 Paterson Street, Causeway Bay, Hong Kong PROXY Solicited on Behalf of the Board of Directors for the Extraordinary General Meeting of Shareholders To be held on October 23, 2026 at 10:30 a.m., Hong Kong Time (October 22, 2026 at 10:30 p.m., Eastern Time) The undersigned hereb…
Read attachment ↗